Published Medical Literature

Are Genetic Variants and Plasma Imatinib Levels Linked to Improved Outcomes in CML?

Second-Generation TKIs for CML: Weighing Clinical Benefits and Cost

Willingness to Discontinue TKI Treatment of CML: Findings From Survey of Patients

Ventricular Fibrillation and Direct ABL Kinase Inhibition in CML: Case Study

Diabetes Mellitus After Nilotinib Treatment for CML: Case Study

Generic Imatinib for CML: Experience From Eastern India

Is Switching TKIs Effective in Achieving Clinical Response in Chronic-Phase CML?

Treatment-Free Remission in CML: An Outcome for All Patients?

Flumatinib Versus Imatinib for Chronic-Phase CML: Phase III FESTnd Trial

Can CRISPR-Knockout Screening Identify Drug Resistance Targets in CML?

Neutrophil Migration Analysis in Atypical CML: Case Study

Case Study in CML: Is Imatinib Treatment Safe During Breastfeeding?

Adding Ropeginterferon Alpha‐2b to Imatinib for Chronic-Phase CML

Accelerated-Phase CML: Is Dasatinib Plus Decitabine Active?

Comorbidities at Diagnosis: Predictive of Outcomes in CML?

Late Molecular Recurrence and Treatment-Free Remission in CML

Does BCR-ABL Transcript Subtype Affect Response to Nilotinib in CML?

Nilotinib for CML With Co-expression of e13a2 and e14a2 Transcripts

Fatigue in Patients With CML: Focus on Physical Activity

Comparing Prognostic Scores in Predicting Outcomes in CML

Is Low-Dose Ponatinib of Benefit in CML After Intolerance to Other Treatments?

Link Between Cognitive Impairment and Outcomes in Older Recipients of Allogeneic HCT?

Impact of Low-Dose Versus Full-Dose TKIs on CML Remission

Erythropoietin Therapy for Patients With CML Who Have Late Anemia

Is Low-Dose Ponatinib of Benefit in CML After Intolerance to Other Treatments?

Incidence of Imatinib-Induced Hypogammaglobulinemia in Children With CML

Chronic Phase CML Outcomes Update in the Era of Multiple TKIs

Predictive Biomarkers of Treatment-Free Remission in CML Under Study

Cardiovascular Risk With Ponatinib Treatment in CML: Focus on Lipid Profile

Trends in Primary Treatment and Survival Among Elderly Patients With CML

Is Molecular Response to Bosutinib or Imatinib Linked to Quality of Life in CML?

Effects of TKI Combinations on Drug Resistance in CML: Focus on Axitinib and Asciminib

Italian Study on Use of Second-Generation TKIs as Front-Line Therapies in CML

Self-Initiated Discontinuation of Nilotinib in CML: Case Report

CML and Cardiovascular Adverse Events After TKI Therapy: Identifying Probable Pathways

CML Pathology and the Quest for Effective Biomarkers

Korean Study Identifies Benefits of Combining Metformin With Nilotinib in CML

Latent Therapeutic Target for Mitigating Inflammation in CML Cells

Role of Long Noncoding RNA H19 in CML

Early Switch to Dasatinib After Suboptimal Response to Imatinib in Chronic Phase CML

Potential Mechanism of Ponatinib-Induced Vascular Toxicity in CML

Case Report of Aggressive Atypical Chronic Myeloid Leukemia

Nilotinib for CML: Case Report of Severe Valvular Aortic Stenosis

Identifying Commonalities Among CML Blast Crisis Cells

TKI Therapy and Donor Lymphocyte Infusion in Relapsed CML

First-Line Imatinib, Dasatinib, and Nilotinib in CML: Comparing Safety and Costs

Anticancer Potential of Tetrahydrobenzimidazole Derivative in CML

Long-Term Efficacy of Nilotinib in Chronic Phase CML

Next-Generation Sequencing for Mutation Testing in CML: Position Paper

Identifying a Tumor Suppressor in Chronic Myeloid Leukemia

Proposed Guidelines for CML Treatment: Treatment-Free Remission Is the Goal

Early Research on Asciminib Plus Ponatinib in Resistant CML

Ponatinib and Chemotherapy for Blast Phase Chronic Myeloid Leukemia

Health-Related Quality of Life in Patients Receiving TKI Therapy for CML

Novel Strategy for Treating CML: Repurpose Existing Anticancer Agents

CML Case Study: Neurologic Symptoms Related to Use of Nilotinib?

Strategy for Overcoming BCR-ABL1^T315I–Positive Clones in Resistant CML

Study Finds Asciminib Active in Heavily Pretreated Patients With CML

Identifying Pathologic Characteristics of NKT-Like Cells in Patients Treated for CML

Study Finds Complex BCR-ABL1 Signal Patterns Linked to Poorer Prognosis in CML

Nilotinib Dosing in Pediatric Patients With CML

Treatment-Free Remission and Dasatinib Discontinuation for Chronic Phase CML

The Bone Marrow Niche in Treatment-Resistant CML: A Review

Advances in Molecular Tools for Monitoring CML

Health-Related Quality-of-Life Outcomes With TKI Therapy in Newly Diagnosed CML

Cognitive Behavioral Therapy via FaceTime for TKI-Related Fatigue in CML

Meta-analysis Compares Front-Line Treatments in Newly Diagnosed Chronic-Phase CML

Using BCR-ABL1 Doubling and Halving Times to Predict Patient Responses in CML

How SOX30 Methylation May Impact Progression of CML

Targeting Leukemic Stem Cells in CML With Immunotherapy

Comparing Front-Line Treatments of Newly Diagnosed Chronic Phase CML

Nilotinib Treatment for Rare CML Fusion Transcript: Case Study

German Population–Based Study Offers Insight Into Use of TKIs for CML

Arsenic Sulfide Nanoformulation and CML Cells

Interaction of BCR-ABL and Beclin-1 in CML

Can Drug Rotation Therapy Delay Resistance to Treatment in CML?

Role of FAM168A Protein in Proliferation of CML Cells

First-Line Imatinib Dosing in Elderly Patients With CML

Evaluating Outcomes for Children With Advanced Phase of CML at Time of Diagnosis

Tyrosine Kinase Inhibitor Rotation Therapy in CML

Axis of Power in Tyrosine Kinase Inhibitor–Resistant CML

CRISPR-Based System Under Study in Resistant CML

Gait Speed and Grip Strength: Predictors of Outcome in Hematologic Malignancies?

Molecular Relapse in CML After TKI Discontinuation

Ten-Year Outcomes With Imatinib Treatment in CML

Review of Potential Therapeutic Options for Drug-Resistant CML

Impact of Health-Care Costs in CML on an Oncology Care Model

Does NUMB Protein Play a Role in Imatinib-Resistant CML?

Does Inhibition of Tumor Necrosis Factor Alpha Affect Tumor Growth in CML?

Role for RNA-Binding Protein in Progression of CML

ENESTnext Trial: Evaluating Molecular Response With Front-Line Nilotinib in CML

Genetic Polymorphism and CML Risk

Shedding Light on Treatment-Resistant Leukemia Stem Cells

Imatinib Discontinuation Among Pediatric Patients With CML

IFN-α in CML: Mediator of CML Stem Cell Exhaustion Identified

Dasatinib in CML: Activating Natural Killer Cells

Review Finds Real-World Studies May Benefit CML Research

Research Sheds Light on Plasmacytoid Dendritic Cells in CML

Mitigating Adverse Events With Bosutinib Treatment in CML

Timely Molecular Monitoring of Patients With CML

Therapeutic Response in de Novo vs. Therapy-Related CML

Conception and Pregnancy in Patients Treated With TKIs for CML

Case of CML Relapse Decades After Stem Cell Transplant

Insights From Observational Study of 1,000+ Patients With CML

Impact of Donor Clonal Hematopoiesis on Stem Cell Transplantation

Rare Case of Autoimmune Hemolytic Anemia in a Patient With CML

Coexistence of CML and Multiple Myeloma: A Case Study

Case Study Highlights Complexities of Cesarean Section in Patient With CML

Can Tyrosine Kinase Inhibitors for CML Affect PSA Titers Unrelated to Prostatic Disease?

Preexisting Drug Resistance in Philadelphia-Positive Leukemias

Analysis of Bone Marrow Stromal Cells in Patients With CML During Chemotherapy

Study Offers Further Support to Long-Term Treatment-Free Remission in CML

TKI Therapy and Its Influence on Quality of Life in Patients With CML

Is Bone Marrow Core Biopsy Always Necessary in Initial Evaluation for CML?

Guidelines for Managing Clostridium Difficile Infection in Younger Transplant Recipients

End-of-Life Care After Allogeneic Hematopoietic Cell Transplantation

Are Patients Treated for Breast Cancer at Increased Risk of CML?

Long-Term Outcomes With Dasatinib in CML in Accelerated Phase

Clinical and Economic Impact of Early Versus Late Molecular Monitoring in CML

Update on Reduced-Intensity Conditioning for Certain Hematologic Malignancies

Investigating Pleural Effusion Associated With Dasatinib Therapy in CML

Long-Term Results With Bosutinib in Chronic-Phase CML

Closer Look at Contribution of Oncogenes to Development of CML

Genetic Susceptibility to Myeloid Malignancies

Attitudes of Patients With CML Toward Treatment-Free Remission

Shedding Light on Imatinib Resistance in CML: Focus on T315I Mutation

Simulation Study Evaluates Dose Reduction of Tyrosine Kinase Inhibitors in CML

Do Tyrosine Kinase Inhibitors Affect Thrombopoietin Levels in Patients With CML?

Treating CML in Pediatric Patients: Is Imatinib Safe and Effective?

Navigating Pregnancy and Tyrosine Kinase Inhibitor Therapy in Women With CML

Is CML Becoming More Prevalent in France?

Patient-Centered Approach to Treatment-Free Remission in CML

Lower Dose of Dasatinib in Newly Diagnosed CML

Managing Side Effects of Bosutinib in Patients With Ph-Positive CML

EURO-SKI Trial: Discontinuation of Tyrosine Kinase Inhibitor Therapy in CML

Switching to Lower Dose of Nilotinib for TKI-Intolerant Patients With CML

Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia

Cardiovascular Health Considerations When Using Tyrosine Kinase Inhibitors

How Common Is Cognitive Impairment Among Older Patients With Blood Cancers?

BFORE Trial: Bosutinib Versus Imatinib in Newly Diagnosed CML

Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia

Review of Tyrosine Kinase Inhibitor Use in Chronic Myeloid Leukemia

Predicting Response to Therapy With TKIs in Patients With Chronic Myeloid Leukemia

Dasatinib Dosing: Balance Between Efficacy and Toxicity

Long-Term Bosutinib Treatment for CML and Health-Related Quality of Life

CML Study IV: 10-Year Survival Results With First-Line Imatinib Treatment

Guidelines for Use of Growth Factors in CML and Other Leukemias